Exploring An 85% Potential Upside In The Biotech Sector
Soleno Therapeutics, Inc. (NASDAQ: SLNO) is capturing investor attention with a potential upside of 85.42%, as analysts set their sights on a promising future for this innovative healthcare player. Operating within the biotechnology industry, Soleno Therapeutics is renowned for its focus on developing novel treatments for rare diseases. Based in Redwood City, California, the company is in the late-stage clinical trial phase for its lead product, Diazoxide Choline Extended-Release tablets, aimed at treating Prader-Willi Syndrome.
With a market capitalization of $3.41 billion, Soleno is a significant player in the biotech sector, even though it currently operates without traditional valuation metrics such as P/E and PEG ratios. This…
